 Breda, the Netherlands Ghent, Belgium argenx Euronext Nasdaq: ARGX, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, announced today that the underwriters of its previously announced global offering of ordinary shares including ordinary shares represented by American Depositary Shares ADSs have exercised their option to purchase 548,777 additional ADSs in full on the same terms and conditions as the global offering. This option exercise brings the anticipated total gross proceeds from the global offering to approximately 862.5 million approximately 784.7 million from the sale of an aggregate of 4,207,292 ordinary shares including ordinary shares represented by ADSs. 